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Abstract 
Background/Aims: Pigmentary retinal dystrophy and macular dystrophy have been 
previously reported in Heimler syndrome due to mutations in PEX1. Here we reported the 
ocular manifestations in Heimler syndrome due to mutations in PEX6. 
Materials and methods: Medical records were reviewed to identify patient demographics, 
ophthalmic and systemic findings, and results of diagnostic testing including whole genome 
sequencing 
Results: Patient 1 is 12-year-old boy with a novel mutation c.275T>G (p.Val92Gly) and 
known mutation c.1802G>A (p.Arg601Gln) in PEX6. Patient 2 is a 7 year- old girl with the 
same known c.1802G>A (p.Arg601Gln) mutation and another novel missense mutation 
c.296G>T (p.Arg99Leu). Both patients exhibited a pigmentary retinopathy. Visual acuity in 
patient 1 was 20/80 and 20/25 following treatment of intraretinal cystoid spaces with 
carbonic anhydrase inhibitors, while patient 2 had visual acuity of 20/20 in both eyes 
without intraretinal cysts. Fundus autofluorescence showed a multitude of hyperfluorescent 
deposits in the paramacular area of both eyes. OCTs revealed significant depletion of 
photoreceptors in both patients and macular intraretinal cystoid spaces in one patient. Full 
field electroretinograms showed normal or abnormal photopic but normal scotopic 
responses. Multifocal electroretinograms were abnormal.  
Conclusions: Heimler syndrome due to biallelic PEX6 mutations demonstrates a macular 
dystrophy with characteristic fundus autofluorescence and may be complicated by 
intraretinal cystoid spaces. 
Keyword: Heimler syndrome, PEX6, Macular dystrophy
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Introduction 
Heimler syndrome was first described by Heimler et al. in 1991.1 This autosomal 
recessive disorder has since been shown to be caused by biallelic mutations in PEX1 or PEX6. 
The cardinal features include acquired sensorineural hearing loss (SNHL), amelogenesis 
imperfecta of the teeth, retinal dystrophy and abnormal nails (punctate leukonychia or 
Beau’s lines). 
Pigmentary retinal dystrophy and macular dystrophy have been previously reported 
in Heimler syndrome.2-5 These prior reports primarily describe the ocular manifestations of 
Heimler syndrome due to mutations in PEX1. We previously reported a brief description of 
the ocular manifestations of one patient with Heimler syndrome due to mutations in PEX6,5 
and now provide more detail about that patient and another. 
Materials and methods: 
This study is an observational, retrospective study. The medical records of all 
patients with the clinical diagnosis of Heimler syndrome seen at the Ocular Genetics Clinic at 
Wills Eye Hospital from 2010 to 2016 were reviewed retrospectively. IRB/Ethics Committee 
ruled that approval was not required for this study. Two patients with the diagnosis of 
Heimler syndrome were identified. Their medical records were reviewed to identify patient 
demographics, ophthalmic and systemic findings, and results of other testing. The patients 
had whole exome sequencing performed at the Leeds Institute of Biomedical and Clinical 
Sciences (Leeds, UK). Testing methodology, genotype results and systemic phenotypes of 
both patients have been previously reported by Smith et al.5  
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Both patients had a full ophthalmic examination by an ocular genetic specialist (AVL), 
including visual acuity, slit lamp and dilated fundus examination. Fundus autofluorescence 
(FAF) images, Goldmann visual fields and spectral domain-optical coherence tomography 
(SD-OCT) images were obtained. Full-field electroretinogram (ffERG) and multifocal 
electroretinogram (mfERG) were performed in accordance with the International Society of 
Clinical Electrophysiology and Vision standards.6 
Results: 
The BCVA, anterior segment examination, fundus examination, color vision and 
cycloplegic refraction for each patient are summarized in Table 1.  
Case 1:  This 12-year-old boy with congenital high frequency sensorineural hearing 
loss (SNHL) was the product of an uncomplicated pregnancy. Family history was 
unremarkable. Initially he presented with delayed speech which resulted in the diagnosis of 
SNHL at 18 months old, requiring hearing aids. He had positional posterior plagiocephaly, 
toe walking and learning disability with normal IQ testing and a normal brain MRI scan. 
Hyperpigmentation was observed along the lines of Blaschko on the left shoulder and arm, 
together with Beau’s lines on both great toe nails (Figure1A), and amelogenesis imperfecta 
on the secondary teeth. Between 5 and 9 years of age, he had occlusion therapy for 
strabismic amblyopia of his right eye. Pigmentary retinal changes were noted at 3 years old. 
He had no nyctalopia or evidence of constricted visual fields. He had continued ophthalmic 
follow up and subsequently was referred to Wills Eye Hospital at age 12 for further 
evaluation. 
 Fundus autofluorescence (FAF) and optical coherence tomography (OCT) images are 
shown in Figure 2. The patient did not have intravenous fluorescein angiography testing.  
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The mfERG showed decreased central and paracentral amplitudes and delayed implicit time 
in both eyes (Figure2). The ffERG waveforms were normal in response to scotopic and 
combined flash stimuli in both eyes, but showed decreased amplitude and delayed implicit 
time of the A- and B-wave in response to single flash photopic stimuli and 30 Hz flicker 
(Figure 2). Goldmann visual fields were normal in both eyes. The patient was treated with 
topical and oral acetazolamide for his intraretinal cystoid spaces and had improvement from 
20/125 to 20/80 in the right eye and 20/40 to 20/25 in the left eye. After 5 years of follow 
up, the patient’s visual acuity was stable with oral acetazolamide as his only medication. 
Karyotype revealed a normal male karyotype. A single nucleotide polymorphism 
(SNP) microarray (Quest Diagnostic Nichols Institute, Chantilly, Virginia) found a 146-kb 
deletion at 5q21.3 and 466 kb duplication at 1p32.1p31.3, both of which were maternally 
inherited. Maternal eye examination status post LASIK surgery showed a mildly shallow 
anterior chamber, bilateral cortical lens flecks, a normal fundus and a normal appearance 
with optical coherence tomography. Paternal eye examination showed high myopic 
astigmatism with bilateral cortical lens flecks and a normal fundus. Sequencing of the exons 
and flanking intronic areas of CNNM4 and NR2E3 (Casey Eye Institute, Portland, OR, USA) 
detected no abnormal findings and no deletions or duplications were found. The 
OtoGenome hearing loss panel of 71 genes (Laboratory for Molecular Medicine, Cambridge, 
MA, USA) was normal. Whole exome sequencing revealed compound heterozygosity in the 
PEX6 gene: a novel mutation c.275T>G (p.Val92Gly) and known mutation c.1802G>A 
(p.Arg601Gln).2 The novel mutation affects a region of the gene that is conserved in 
mammalian species.5 Both SIFT and Mutation-Taster programs predict pathogenicity. 
PolyPhen-2 predicts the change to be probably damaging. The known mutation c.1802G>A 
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is maternally inherited and the novel mutation c.275T>G is paternally inherited. This patient 
is Family2 in Smith et al.5 
Case 2: This 7 year- old girl is the product of an uncomplicated pregnancy born to a 
33-year-old mother, who has a periauricular skin tag, hypoglossal duct surgery and 
hypothyroidism, and a healthy 36-year-old father. There is no known consanguinity. Family 
history is otherwise unremarkable except for the patient’s brother who had hydronephrosis 
requiring bilateral ureteral implantation surgery. Our patient had a normal voiding 
cystourethrogram (VCUG) in the neonatal period. 
She was entirely well until 3 years old when she was diagnosed with bilateral 
sensorineural hearing loss, requiring hearing aids, with normal speech (Figure 1B). She had 
amelogenesis imperfecta of her primary and secondary molars (Figure 1C). Nails were 
normal.  She had a small cutaneous capillary hemangioma on her right lower chest. Between 
3 and 5 years old, she was treated for amblyopia in her left eye with patching and glasses.  
At 7 years old, retinal pigmentary changes were found. Her night vision was normal, but she 
sometimes had photophobia. She was referred to Wills Eye Hospital for further evaluation. 
FAF and OCT images are shown in Figure 3. FfERG waveforms were normal in 
response to scotopic stimuli, photopic stimuli, combined flash and 30Hz flicker (Figure 3). 
MfERG waveforms were decreased in amplitude paracentrally in response to 
pseudorandom honeycomb pattern stimuli in both eyes (Figure 3). The responses were 
slightly better centrally and peripherally. Goldmann visual fields were normal. 
SNP Microarray analysis (Quest Diagnostic Nichols Institute, Chantilly, VA, USA) was 
normal. OtoChip screening (Molecular Otolaryngology and Renal Research Laboratories, IA, 
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USA) was negative. Sequencing of the exons and flanking intronic areas of CNNM4 (Casey 
Eye Institute, Portland, OR, USA) was normal and no deletions or duplications were found. 
Whole exome sequencing revealed compound heterozygosity for mutations in PEX6, these 
being the known mutation2 c.1802G>A (p.Arg601Gln) mutation and a novel missense 
mutation c.296G>T (p.Arg99Leu). The novel mutation affects a region of the gene that is 
conserved in mammalian species.5 The Mutation-Taster program predicts pathogenicity. 
PolyPhen-2 predicts the change to be probably damaging while SIFT predicts this variation 
to be non-deleterious. The known mutation c.1802G>A is maternally inherited and the novel 
mutation c.296G>T is paternally inherited. This patient is Family 3 from Smith et al.5 
Discussion: 
The ocular manifestations of Heimler syndrome were first reported by Lima et al., who 
characterized the macular dystrophy in a 29-year-old female, later shown to be compound 
heterozygous for mutations in PEX14. Key findings included decreased visual acuity with 
“salt and pepper” fundus, hyper and hypoautofluorescent dots in the posterior pole and 
periphery of the retina, loss of the “inner/outer segment boundary” and RPE thinning in OCT 
with normal ffERG. Ratbi et al. described “retinal pigmentation”, macular dystrophy and 
visual impairment, and more recently, retinitis pigmentosa.  Smith et al. described 6 families 
with Heimler syndrome.  Five had initially been misdiagnosed as Usher syndrome. The 
ocular findings were briefly described in one patient with PEX6 mutations who is our patient 
2. Families 2 and 3 described by Smith et al. are our patients 1 and 2, respectively.2 We 
herein report further detailed characterization of their ocular phenotype. To the best of our 
knowledge, our cases represent the first report of detailed characterization of the ocular 
findings in Heimler syndrome due to mutations in PEX6. 
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Heimler syndrome exhibits phenotypic variability. SNHL can be unilateral or bilateral and 
nails can be normal.7-8 Amelogenesis imperfecta usually manifests in secondary teeth, with 
posterior (premolar and molar) teeth more severely affected than anterior (incisor) teeth.  
Amelogenesis imperfecta is also seen in Jalili syndrome,9 hyperbilirubinemia, premature 
birth, hypoparathyroidism, viral infections and in response to excessive fluoride or 
tetracycline. Jalili syndrome is associated with cone-rod dystrophy and is therefore relevant 
to the differential diagnosis in our patient, although our patient did not have mutations in 
CNNM4.  
Our case 1 had typical findings of Heimler syndrome including SNHL, amelogenesis 
imperfecta and abnormal nails. He also had posterior plagiocephaly, toe walking and 
learning disability. Posterior plagiocephaly without lambdoidal synostosis is frequent in the 
general population when positional and is likely unrelated. SNP microarray revealed a 146-
kb deletion at 15q21.3 and 466 kb duplication at 1p32.1p31.3, both inherited from his 
unaffected mother, suggesting that these copy number variations are likely benign. 
Sequencing of CNNM4 was negative and screening with the OtoGenome hearing loss panel 
was normal. Delayed development with amelogenesis imperfecta had been reported with 
mutations in PEX6.5 Patient 2 also had findings typical of Heimler syndrome, including SNHL 
and amelogenesis imperfecta. SNP microarray analysis, CNNM4 sequencing and 
deletion/duplication analysis were normal. Whole exome sequencing revealed PEX6 
pathogenic sequence changes in both patients.5 
The discovery that hypomorphic PEX1 and PEX6 mutations cause Heimler 
syndrome2,5 identifies the condition as a peroxisomal disorder. One study suggests that 
mutations in PEX1 are more common2  while another found PEX6 mutations to be more 
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common.5 Other peroxisomal disorders include Zellweger syndrome, neonatal 
adrenoleukodystrophy (NALD), infantile Refsum disease (IRD) and chondrodysplasia 
punctata.  Mutations in PEX1 and PEX6 may also result in a form of Zellweger syndrome, 
which is characterized by craniofacial abnormalities, neurologic dysfunction, and liver 
dysfunction.10-11 Ocular manifestations were not specifically described.   In other forms of 
Zellweger syndrome, some of which were not molecularly defined, ocular findings include 
nystagmus, cloudy corneas, glaucoma, cataract, retinal dystrophy with extinguished ERG, 
macular intraretinal cystoid spaces and optic atrophy.10,12-18 Our patients, and those 
reported by Ratbi and Lima, had a milder form of retinal dystrophy compared to other 
patients with Zellweger syndrome.   
The peroxisome is a cytoplasmic organelle. Its main function is the breakdown of 
very long chain fatty acids through beta-oxidation. The PEX1 and PEX6 proteins bind with 
adenosine triphosphate (ATP) to form a heterohexameric ATPase which is associated with 
various cellular activities that fuel essential protein transport across peroxisomal 
membranes, the final steps of peroxisomal matrix-protein import.19-23 PEX1 and PEX6 are 
expressed in the retina, especially in photoreceptors.24 Abnormal PEX6 and PEX1 proteins 
result in abnormal peroxisomal function, leading to the accumulation of very long chain 
fatty acids.  Histopathology of other peroxisomal disorders shows accumulation of 
characteristic bileaflet fatty acid inclusions in photoreceptors, RPE and pigment laden 
macrophages.13 Fatty acid accumulation may create the lipofuscin-like substances which 
appear as hyperfluorescent flecks seen on FAF in our patients. 
Our patients showed similarities to and differences from the ocular manifestations 
resulting from the mutations in PEX1. Visual acuity in our case 1 and Lima’s patients showed 
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asymmetrical visual loss, while patient 2 had BCVA of 20/20 in both eyes. The decreased 
vision in the right eye in patient 1 may be attributed, in part, to strabismic amblyopia or the 
macular cysts, or a combination of both. Anterior segments were normal, except our case 1 
which had mild cortical cataract, which has not previously been reported in Heimler 
syndrome. OCT revealed intraretinal cystoid spaces in the outer plexiform layer in our case 
1, Lima’s patient and Ratbi’s patient. We found mottling of the macular RPE and 
hyperfluorescent deposits with central macular sparing by FAF in our patients as also 
reported by Lima et al.  
FfERGs were normal in patient2 and showed mild photopic abnormalities in patient1 
which differs from Ratbi’s patient, who harbored PEX1 mutations and showed abnormal 
scotopic and photopic responses. The mfERG in our patients are abnormal, consistent with 
the observed macular dystrophy as also reported by Lima.4 The patient of Lima et al. was 
more severely affected. This may be due to the patient’s older age (29 years old) or may 
perhaps suggest a more potent effect of PEX1 mutations. The patient of Ratbi et al., had a 
retinitis pigmentosa phenotype not seen in our patients. We had personal communication 
with the physician of the patients from family 5 in Smith et al.5 A pair of siblings with 
Heimler syndrome who harbored PEX6 mutation, they had a retinitis pigmentosa phenotype 
with intraretinal cystoid spaces similar to Ratbi’s patient.3 Our ERG findings suggest a 
predominant effect of the PEX6 mutation on the cone system which may be due to fatty 
acid deposition in macula as shown by FAF. 
The intraretinal cystoid spaces in our case 1 may or may not represent cystoid 
macular edema. IVFA had not been done to distinguish these possibilities. The patient was 
treated with topical and oral acetazolamide and had some improvement of visual acuity and 
Macular Dystrophy in Heimler Syndrome 
remained stable after 5 years follow-up with oral acetazolamide as his maintenance 
medication. The patient reported by Lima et al. showed non-leaking intraretinal cystoid 
spaces by IVFA.  Treatment details were not provided. Ratbi’s patient, who had been treated 
with oral acetazolamide, intravitreal triamcinolone acetonide and intravitreal ranibizumab, 
did not show resolution of intraretinal cystoid spaces. The OCTs of our patients were 
variable and not particularly correlated with their vision as previously reported.25  
In conclusion, we report the ocular findings of Heimler syndrome due to PEX6 
mutations. Ophthalmic examination can be helpful in this disorder, showing a characteristic 
pattern on FAF along with changes on OCT, ffERG, and mfERG.  Patients with intraretinal 
cystoid spaces may benefit from carbonic anhydrase therapy. Long term follow-up is 
required to better understand the ocular prognosis of this disease. Heimler syndrome, and 
ocular examination with diagnostic testing, should be considered in patients with SNHL or 
amelogenesis imperfecta. 
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